Introduction {#s1}
============

Acute variceal bleeding ([@B8]) (AVB) is a severe and emergency complication associated with a 20% mortality at 6 weeks in patients with advanced cirrhosis. As the most life-threatening complication in cirrhosis patients, this medical field has received significant attention. Over the past few decades, the recommended standard treatment for patients with AVB involves a combination of endoscopic therapy, vasoactive drugs, and antibiotic therapy ([@B14]; [@B36]; [@B15]). Nevertheless, the curative effects are not as good as we expected, including treatment failure occurring in 10-20% of patients, an inevitable risk of rebleeding within the first 48--72 hours, and over 50% of rebleeding episodes occurring within the first 10 days required further rescue therapy---especially in patients with high risk of treatment failure or rebleeding (patients with Child-Pugh C or Child-Pugh B with acute bleeding on endoscopy) ([@B8]; [@B27]).

A transjugular intrahepatic portosystemic shunt (TIPS) procedure is a minimally invasive, image-guided intervention used for the prevention of rebleeding and as salvage therapy in patients with refractory variceal hemorrhage, instead of first-line therapy ([@B21]; [@B30]). However, studies show that worsening liver function occurred in those patients, which remains high (27%-55%) and also plays a key role as a predictive factor in poor prognosis such as sepsis, hepatic encephalopathy, shock, and death ([@B7]; [@B3]; [@B5]; [@B35]). In recent years, research ([@B26]; [@B12]; [@B13]; [@B31]; [@B6]; [@B22]; [@B23]) aimed at exploring whether early-TIPS (placed within 72 hours after esophagogastroduodenoscopy (EGD) or endoscopic variceal ligation (EVL)) could replace standard therapy (EVL *plus* NSBB *plus* ANTIBIOTICS) as first-line therapy in AVB is increased. Several RCTs ([@B25]; [@B12]) demonstrated a significantly lower rebleeding rate, with no change in mortality, and a higher incidence of hepatic encephalopathy in patients who received TIPS. The 2017 Practice Guidance ([@B15]) by the American Association for the Study of Liver Diseases (AASLD) also recommend that the early-TIPS procedure should be placed in patients with a high risk of treatment failure or rebleeding. Nevertheless, whether early-TIPS could reduce the mortality and risk of hepatic encephalopathy remains controversial. There has only been one meta-analysis ([@B9]) in 2015 which did not report on the short-term (6 weeks) mortality and rebleeding risk. Therefore, new research revealing early-TIPS, with its current standard therapy, is necessary and beneficial for clinical practice.

In this study, we performed a systemic review with a meta-analysis evaluating whether early-TIPS should be the first-line therapy for current standard care of AVB in cirrhosis patients.

Methods {#s2}
=======

Data Sources and Literature Searches {#s2_1}
------------------------------------

This systemic review and meta-analysis was based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (PRISMA) ([@B25]) and conducted using the Cochrane Collaboration\'s systematic review framework ([@B20]). PubMed, EMBASE, and the Cochrane Library were searched up until 25 June 2019 for eligible studies investigating early-TIPS versus pharmacotherapy, EVL, and combination therapy in patients with AVB, using the following MeSH words and key terms: "esophageal varices", "variceal rebleeding", "variceal hemorrhage", "portal hypertension", "liver cirrhosis", "pharmacotherapy", "endoscopic variceal ligation", "TIPS", "early-TIPS", and "transjugular intrahepatic portosystemic shunt".

Literature Selection and Exclusion {#s2_2}
----------------------------------

Studies were included in this systemic review and meta-analysis if they met the following criteria: (1) Patients over 16 years old with acute esophageal varices in cirrhosis (or combined gastric varices, but not gastric varices only); (2) PTFE-covered TIPS was placed within 72h after the index bleeding or esophagogastroduodenoscopy or endoscopic therapy; (3) RCTs and non-RCTs compared early-TIPS with standard therapy (defined as a combination of pharmacotherapy *plus* endoscopic therapy). The primary outcomes were defined as the treatment failure (defined as refractory bleeding or rebleeding within 5 days), short-term (during 6-weeks follow up) all-cause mortality and rebleeding risk, and risk of hepatic encephalopathy. Secondary outcomes were defined as the long-term (during 1-year follow up) all-cause mortality and rebleeding risk, risk of new or worsening ascites, rate of liver transplantation, and risk of mortality caused by rebleeding.

Exclusion criteria were the following: (1) TIPS was placed as a rescue therapy; (2) patients with hepatocellular carcinoma (HCC) that did not meet the Milano criteria ([@B24]) for transplantation; (3) a history of previous use of a portosystemic shunt or TIPS; (4) bleeding from isolated gastric or ectopic varices; (5) patients with total portal-vein thrombosis; (6) patients \> 75 years; (7) patients with severe systemic disease (renal failure, heart failure, etc.).

Data Extraction {#s2_3}
---------------

Two independent reviewers extracted relevant data from the eligible studies. When it came to disagreements, consultation was carried out with a third reviewer. The relevant data consists of study design, patient characteristics, interventions, controls, and outcomes.

Quality Assessment of Included Studies {#s2_4}
--------------------------------------

The Newcastle-Ottawa Scale (NOS) was used to evaluate the methodological quality of non-RCTs studies by two independent commentators. Studies that achieved six or more stars on the modified NOS were considered high quality ([@B32]). To evaluate risk of bias for RCTs by two independent commentators, the Cochrane Collaboration tool ([@B19]) for assessment of bias was performed, which considers seven domains including adequacy of sequence generation, allocation concealment, blinding of participants, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other potential sources of bias, and each item was graded as "high risk", "low risk", or "unclear".

Statistical Analysis {#s2_5}
--------------------

The dichotomous outcomes ([@B20]) were expressed as the odds ratio (OR) with a 95% confidence interval (CI). Heterogeneity ([@B18]) between studies was assessed by the I^2^ statistic, in which the significance level was set to P \<0.1. To qualify the inconsistency between studies, when I^2^ \<40%, we considered that the heterogeneity was mild, then a fixed effect model was performed. However, considering the possibility of heterogeneity between studies, when I^2^ \>40%, the heterogeneity was considered non-negligible, therefore, the random effect model was performed instead of the fixed effect model.

Based on the diversity of studies, it is unavoidable to observe the heterogeneity in outcomes. Therefore, a subgroup analysis was conducted by variate of Child-Pugh class (Child-Pugh B and Child-Pugh C) and study design (RCTs and non-RCTs) to explore the source of heterogeneity. For studies of population enrolled patients with Child-Pugh A, which are not considered suitable participants in the AASLD guideline ([@B15]), we excluded these studies in primary outcomes for sensitivity analysis to detect the stability of the results. In addition, the Egger\'s test ([@B11]) was conducted to detect potential publication bias, and all the statistical analyses were performed by Stata 12.0.

Results {#s3}
=======

Characteristics of Eligible Studies {#s3_1}
-----------------------------------

Our systematic literature search identified 1,778 potential publications. Based on the selection criteria, independent reviewers obtained quantitative data for our meta-analysis by reading all titles, abstracts, and full text evaluations. Eventually, five studies ([@B12]; [@B13]; [@B31]; [@B22]; [@B23]) were included with 1,754 (398 of early-TIPS and 1,356 of standard therapy) enrolled participants, two of them were RCTs ([@B12]; [@B22]), and the other three were non-RCT ([@B13]; [@B31]; [@B23]) ([**Figure 1**](#f1){ref-type="fig"}). The characteristics of each individual study are presented in [**Table 1**](#T1){ref-type="table"}. The reasons for exclusion of literature are presented in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}.

![Selection process of included studies.](fphar-11-00603-g001){#f1}

###### 

Characteristics of included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References   Study design   Mean age\   Gender    Etiology of cirrhosis^\*^   Child-Pugh class^\*^   Standard/Early-TIPS   Type of TIPS   Follow-up (month)\*                                                           
                              (mean)\*                                                                                                                                                                                    
  ------------ -------------- ----------- --------- --------------------------- ---------------------- --------------------- -------------- --------------------- ------- ------------------------------------- --------- -----------
  [@B12]       RCT            49/52       44/19     20/22                       5/4                    31/32                 0/0            16/16                 15/16   Pharmacotherapy *plus* EVL;\          Covered   10.6/14.6
                                                                                                                                                                          TIPS was performed within 72 hours              

  [@B13]       Non-RCT        55/56       52/21     18/25                       4/5                    30/45                 0/0            10/18                 20/27   Pharmacotherapy *plus* EVL;\          Covered   14.6/13.1
                                                                                                                                                                          TIPS was performed within 72 hours              

  [@B31]       Non-RCT        52.4/53.2   49/13     77/77                       3/7                    31/31                 NA             NA                    NA      Pharmacotherapy *plus* EVL;\          Covered   7.8
                                                                                                                                                                          TIPS were performed within 72 hours             

  [@B22]       Non-RCT        52/54       984/441   123/14                      743/\                  1219/\                455/\          654/\                 88/33   Pharmacotherapy *plus* EVL;\          Covered   23.4/22.9
                                                                                133                    206                   40             131                           TIPS was performed within 72 hours              

  [@B23]       RCT            50.9/50.7   87/42     4/2                         38/65                  45/84                 0/0            35/65                 10/19   Pharmacotherapy *plus* EVL;\          Covered   24/24
                                                                                                                                                                          TIPS was placed within 72 hours                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Data was expressed as standard therapy versus early-TIPS. TIPS, transjugular intrahepatic portosystemic shunt; NA, not available; EVL, endoscopic variceal ligation; RCT, randomized controlled trail.

Quality of Included Studies {#s3_2}
---------------------------

Three cohort studies ([@B13]; [@B31]; [@B6]) were assessed by NOS ([@B32]), the methods for determining exposure factors were reasonable, however, there were some patients in the studies who suffered hepatic encephalopathy at the start, which was considered a primary outcome in our studies. In addition, the other item did not miss the score, therefore, the scores of all studies were more than six as shown in [**Supplementary Table 2**](#SM1){ref-type="supplementary-material"}, available online.

The Cochrane risk of bias tool ([@B19]) demonstrated no high bias in two included RCTs ([@B12]; [@B22]), and the outcomes are shown in [**Supplementary Table 3**](#SM1){ref-type="supplementary-material"}, available online.

Primary Outcomes {#s3_3}
----------------

### Treatment Failure {#s3_3_1}

Five studies ([@B14]; [@B13]; [@B31]; [@B22]; [@B23]) reported this outcome with eight (2.0%) in the early-TIPS group and 235 (17.3%) in the standard treatment group. As expected, early-TIPS showed a statistical significance to prevent treatment failure in patients with a low statistic difference (OR=0.11, 95%CI= 0.05-0.23, P\<0.001; I^2^ = 0%, P=0.721) shown in [**Figure 2**](#f2){ref-type="fig"}.

![Forest plot demonstrating treatment failure, short-term mortality (6-weeks) and short-term rebleeding risk (6-weeks).](fphar-11-00603-g002){#f2}

Subgroup analysis shown in [**Table 2**](#T2){ref-type="table"} demonstrated a significant reduction in RCTs (OR=0.13, 95%CI=0.03-0.58, P=0.008; I^2^ = 0%, P=0.520), and non-RCTs (OR=0.11, 95%CI=0.04-0.25, P\<0.001; I^2^ = 0%, P=0.437).

###### 

The results of subgroup analysis in all outcomes.

  ----------------------------------------------------------------------------------------------------------------------------------
  Outcomes                         Studies\   Early-TIPS/\   Percentage (%)   OR     95%CI        P for OR   I^2^ (%)   P for I^2^
                                   (n)        Standard                                                                  
  -------------------------------- ---------- -------------- ---------------- ------ ------------ ---------- ---------- ------------
  **Treatment failure**            5          8/235          2.0/17.3         0.11   0.05-0.23    \<0.001    0          0.721

  RCTs                             2          2/10           17.2/13.2        0.13   0.03-0.58    0.008      0          0.520

  Non-RCTs                         3          6/225          2.1/16.6         0.11   0.04-0.25    \<0.001    0          0.437

  **6-weeks mortality**            4          11/146         3.1/11.0         0.24   0.13-0.46    \<0.001    8.9        0.349

  RCTs                             2          2/16           1.7/21.1         0.07   0.02-0.33    0.001      0          0.925

  Non-RCTs                         2          9/130          3.8/10.4         0.32   0.16-0.65    0.002      0          0.667

  **6-weeks rebleeding**           5          15/268         3.8/19.8         0.21   0.12-0.36    \<0.001    0          0.443

  RCTs                             2          1/10           0.9/13.2         0.09   0.02-0.53    \<0.001    0          0.507

  Non-RCTs                         3          14/258         5.0/20.2         0.23   0.13-0.40    \<0.001    21.7       0.279

  **Hepatic encephalopathy**       5          151/392        15.1/18.6        1.29   0.996-1.67   0.054      35.4       0.185

  RCTs                             3          37/28          31.9/36.7        0.78   0.42-1.45    0.438      0          0.377

  Non-RCTs                         3          114/364        40.4/28.4        1.16   1.08-1.90    0.012      14.7       0.309

  **1-year mortality**             5          60/253         15.1/18.6        0.64   0.46-0.90    0.010      38.4       0.165

  Child-Pugh B                     4          33/297         20/43.7          0.34   0.25-0.58    \<0.001    0          0.470

  Child-Pugh C                     4          17/56          22.4/44.5        0.35   0.18-0.68    0.002      10.1       0.329

  RCTs                             2          16/24          13.8/40.2        0.36   0.17-0.73    0.005      0          0.374

  Non-RCTs                         3          44/229         15.6/17.9        0.75   0.52-1.08    0.122      27.2       0.253

  **1-year rebleeding**            5          34/442         8.5/32.6         0.16   0.07-0.36    \<0.001    52.7%      0.076

  RCTs                             2          9/22           7.8/28.9         0.17   0.02-1.56    0.116      73.3       0.053

  Non-RCTs                         3          25/420         8.9/31.7         0.12   0.39-0.40    \<0.001    57.1       0.097

  **Bleeding-related mortality**   4          1/95           0.3/7.2          0.07   0.02-0.29    \<0.001    0          0.989

  RCTs                             1          0/5            0/16.1           0.07   0.004-1.40   0.083      NA         NA

  Non-RCTs                         3          1/90           0.4/7.0          0.07   0.02-0.33    0.001      0          0.940

  **Mortality by liver failure**   5          33/82          8.3/6.0          1.33   0.84-2.12    0.222      1          0.400

  RCTs                             2          6/5            5.2/6.6          0.71   0.21-2.38    0.580      7.2        0.299

  Non-RCTs                         3          27/77          9.6/6.0          1.50   0.91-2.46    0.111      13.6       0.314

  **Liver transplantation**        5          36/88          9.0/6.5          1.36   0.86-2.15    0.183      0          0.891

  RCTs                             2          6/3            5.2/3.9          1.66   0.39-6.94    0.491      0          0.668

  Non-RCTs                         3          30/85          10.6/6.6         1.33   0.82-2.16    0.247      0          0.652

  **Ascites (new/worsening)**      4          33/158         9.0/11.9         0.33   0.21-0.53    \<0.001    0          0.445

  RCTs                             2          19/29          16.4/38.2        0.30   0.15-0.60    0.001      0          0.431

  Non-RCTs                         2          14/129         5.6/10.3         0.30   0.12-0.76    0.001      49.6%      0.159
  ----------------------------------------------------------------------------------------------------------------------------------

TIPS, transjugular intrahepatic portosystemic shunt; RCT, randomized controlled trail; NA, not available; RR, relative risk; CI, confidence interval.

Short-Term Mortality (6 Weeks) {#s3_4}
------------------------------

Four studies ([@B12]; [@B31]; [@B22]; [@B23]) reported this outcome with a total of 11 (3.1%) patients receiving early-TIPS versus 146 (11.0%) receiving standard therapy and who died at 6 weeks (OR=0.24, 95%CI= 0.13-0.46, P\<0.001; I^2^ = 8.9%, P=0.349) in [**Figure 2**](#f2){ref-type="fig"}, which demonstrated a significant improvement on 6 weeks survival in early-TIPS.

A subgroup analysis in [**Table 2**](#T2){ref-type="table"} by study type demonstrated a significant decrease in non-RCTs (OR=0.32, 95%CI=0.16-0.65, P=0.002; I^2^ = 0%, P=0.667), and RCTs (OR=0.07, 95%CI=0.02-0.33, P=0.001; I^2^ = 0%, P=0.925).

### Short-Term Recurrent Bleeding (6 Weeks) {#s3_4_1}

Five studies ([@B12]; [@B13]; [@B31]; [@B22]; [@B23]) reported this outcome. A total of 15 (3.8%; in early-TIPS) and 268 (19.8%; in standard treatment) patients had recurrent bleeding between 5 days and 6 weeks. A significant greater effect on preventing rebleeding at 6 weeks was obtained in early-TIPS (OR=0.21, 95%CI= 0.12-0.36, P\<0.001; I^2^ = 0%, P=0.443) in [**Figure 2**](#f2){ref-type="fig"}.

A subgroup analysis in [**Table 2**](#T2){ref-type="table"} demonstrated a significant reduction in RCTs (OR= 0.09, 95%CI=0.02-0.53, P\<0.001; I^2^ = 0%, P=0.507) and non-RCTs (RR=0.23, 95%CI=0.13-0.40, P\<0.001, I^2^ = 21.7%; P=0.279).

### Hepatic Encephalopathy {#s3_4_2}

Five studies ([@B12]; [@B13]; [@B31]; [@B22]; [@B23]) reported this outcome with an overall 151 (15.1%) and 392 (18.6%) patients suffering hepatic encephalopathy in early-TIPS and standard therapy, respectively. However, there was no connection observed for increasing risk of hepatic encephalopathy for the early-TIPS group, compared to standard therapy (OR=1.29, 95%CI= 0.996-1.67, P=0.054; I^2^ = 35.4%, P=0.185) in [**Figure 4**](#f4){ref-type="fig"}.

A subgroup analysis in [**Figure 2**](#f2){ref-type="fig"} demonstrated no statistically significant difference in RCTs (OR=0.78, 95%CI=0.42-1.45, P=0.438; I^2^ = 0%, P=0.377). Nevertheless, an increasing risk was observed in non-RCTs (OR=1.16, 95%CI=1.08-1.90, P=0.012; I^2^ = 14.7%, P=0.309).

Secondary Outcomes {#s3_5}
------------------

### Long-Term Mortality (1 Year) {#s3_5_1}

Five studies ([@B12]; [@B13]; [@B31]; [@B22]; [@B23]) reported this outcome with an overall 60 (15.1%) and 253 (18.6%) patients who died during 1 year in the early-TIPS and standard care group, respectively. No Significant heterogeneity was observed, when assessed mortality at 1 year (OR=0.64, 95%CI= 0.46-0.90, P=0.010; I^2^ = 38.4%, P=0.165) in [**Figure 3**](#f3){ref-type="fig"}.

![Forest plot demonstrating long-term mortality (1-year) and subgroup analysis according to Child-Pugh class.](fphar-11-00603-g003){#f3}

A subgroup analysis in [**Table 2**](#T2){ref-type="table"} by RCTs and non-RCTs demonstrated a significant difference in them (RCTs: OR=0.36, 95%CI=0.17-0.73, P=0.005, I^2^ = 0%, P=0.374; non-RCTs: OR=0.75, 95%CI=0.52-1.08, P=0.122; I^2^ = 27.2%, P=0.253). Furthermore, a significant reduction in 1-year mortality, according to different Child-Pugh classes, was also observed (Child-Pugh B: OR=0.34, 95%CI=0.25-0.58 P\<0.001; I^2^ = 0%, P=0.470 and Child-Pugh C: OR=0.35, 95%CI=0.18-0.68, P=0.002; I^2^ = 10.1%, P=0.329) in [**Figure 3**](#f3){ref-type="fig"}.

### Long-Term Rebleeding (1 Year) {#s3_5_2}

Five studies ([@B12]; [@B13]; [@B31]; [@B22]; [@B23]) with an overall 34 (8.5%) and 442 (32.6%) recorded patients in early-TIPS and standard treatment, respectively. A significant decrease in rebleeding risk with moderate heterogeneity was observed in early-TIPS compared to standard care (OR=0.16, 95%CI= 0.07-0.36, P\<0.001; I^2^ = 52.7%, P=0.076) in [**Table 2**](#T2){ref-type="table"}.

A subgroup analysis in [**Table 2**](#T2){ref-type="table"} demonstrated that there was no statistical significance in RCTs (OR=0.17, 95%CI=0.02-1.56, P=0.116, I^2^ = 73.3%, P=0.053). On the contrary, a significant decrease was observed in non-RCTs (OR=0.12, 95%CI=0.04-0.40, P=0.001; I^2^ = 57.1%, P=0.097).

### Mortality Caused by Bleeding {#s3_5_3}

Four studies ([@B12]; [@B31]; [@B22]; [@B23]) reported this outcome with 1 (0.3%) and 95 (7.2%) patients who died in early-TIPS and standard therapy, respectively. A significant improvement was observed in patients treated with early-TIPS compared to standard care for preventing bleeding-related mortality during a 1 year follow up (OR=0.07, 95%CI=0.02-0.29, P\<0.001; I^2^ = 0%, P=0.989) in [**Table 2**](#T2){ref-type="table"}.

A subgroup analysis in [**Table 2**](#T2){ref-type="table"} demonstrated that early-TIPS showed a prior protective effect with no heterogeneity in non-RCTs (OR=0.07, 95%CI=0.02-0.33, P=0.001; I^2^ = 0%, P=0.940). However, no difference was observed in RCTs (OR=0.07, 95%CI=0.004-1.40, P=0.083; I^2^=NA, P=NA).

### Mortality Caused by Liver Failure {#s3_5_4}

Five studies ([@B12]; [@B13]; [@B22]; [@B23]) reported this outcome with 33 (8.3%) and 82 (6.0%) patients in early-TIPS and standard therapy, respectively. No statistically significant difference was observed in early-TIPS compared to standard therapy (OR=1.33, 95%CI=0.84-2.12, P=0.222; I^2^ = 1%, P=0.400) in [**Table 2**](#T2){ref-type="table"}.

A subgroup analysis in [**Table 2**](#T2){ref-type="table"} demonstrated no difference in RCTs (OR=0.71, 95%CI=0.21-2.38, P=0.580; I^2^ = 7.2%, P=0.229) and non-RCTs (OR=1.50, 95%CI=0.91-2.46, P=0.111; I^2^ = 13.6%, P=0.314).

### Liver Transplantation {#s3_5_5}

Five studies ([@B12]; [@B13]; [@B31]; [@B22]; [@B23]) reported this outcome with 36 (9.0%) and 88 (6.5%) patients in early-TIPS and standard therapy, respectively. There was no statistic difference in the two groups (OR=1.36, 95%CI=0.83-2.15, P=0.183; I^2^ = 0%, P=0.891) in [**Table 2**](#T2){ref-type="table"}.

A subgroup analysis in [**Table 2**](#T2){ref-type="table"} demonstrated that no significant difference was observed in RCTs (OR=1.66, 95%CI=0.39-6.94, P=0.491; I^2^ = 0%, P=0.668) and non-RCTs (OR=1.33, 95%CI=0.82-2.16, P=0.247; I^2^ = 0%, P=0.652).

### New or Worsening Ascites {#s3_5_6}

Four studies ([@B12]; [@B13]; [@B22]; [@B23]) reported this outcome, in which an overall 33 (9.0%) and 158 (11.9%) recoded patients suffered new or worsening ascites in early-TIPS and standard therapy, respectively. A significant lower risk of new or worsening ascites events was obtained in early-TIPS (OR=0.30, 95%CI= 0.21-0.53, P\<0.001; I^2^ = 0%, P=0.445) in [**Figure 4**](#f4){ref-type="fig"}.

![Forest plot demonstrating risk of hepatic encephalopathy and new or worsening ascites.](fphar-11-00603-g004){#f4}

A subgroup analysis in [**Table 2**](#T2){ref-type="table"} demonstrated a significant difference in RCTs (OR=0.30, 95%CI=0.15-0.60, P=0.001; I^2^ = 0%, P=0.431) and non-RCTs (OR=0.30, 95%CI=0.12-0.76, P=0.001; I^2^ = 49.6%, P=0.159).

Sensitivity Analysis {#s3_6}
--------------------

No differences from the previous results were observed in the sensitivity analysis of excluding Child-Pugh A for three primary outcomes (treatment failure: OR=0.13, 95%CI=0.04-0.47, P=0.002; I^2^ = 0%, P=0.808, 6-weeks mortality: OR=0.07, 95%CI=0.02-0.33, P=0.001; I^2^ = 0%, P=0.925, and 6-weeks rebleeding: OR=0.2, 95%CI=0.10-0.40, P=0.007; I^2^ = 12.0%, P=0.321). In addition, the sensitivity analysis showed that early-TIPS would not increase the risk of hepatic encephalopathy (OR=1.80, 95%CI=0.66-4.92, P=0.253; I^2^ = 0%, P=0.900).

Publication Bias {#s3_7}
----------------

The Egger\'s test was carried out to detect publication bias in our outcomes, and demonstrated no publication bias in most of our outcomes, except in hepatic encephalopathy (P=0.003).

Discussion {#s4}
==========

Despite the fact that almost 20% of patients suffered refractory bleeding or rebleeding and required a rescue TIPS procedure, standard therapy (pharmacotherapy *plus* endoscopic therapy) has been widely performed for decades, profiting from the obvious effect on hemostasis and especially immediate performance during endoscopic examination, while the variceal was actively bleeding. Based on current guidelines ([@B15]), studies exploring the role of early-TIPS in management of acute variceal bleeding and refining the target population that will benefit from this treatment, is indispensable in further research. We carried out this systematic review and meta-analysis, evaluating the effect on early-TIPS procedure in advanced cirrhosis patients with AVB compared to current standard therapy.

In this study, significant decreases in 6 weeks mortality and treatment failure (considered as the main outcomes by Baveno VI consensus ([@B8])) were identified. These results were consistent with the AASLD guideline ([@B15]), in which considering early-TIPS could improve survival at 6 weeks and avoid treatment failure for AVB patients. Early-TIPS also showed a preventative effect on short-term rebleeding. The main determinant of improvement in survival ([@B29]) and rebleeding risk is probably based on a higher rate of bleeding control which benefits form reduction in portal hypertension. Monescillo et al. found that more active bleeding at urgent endoscopy and a greater rate of treatment failure were always associated with higher portal hypertension, therefore, patients with a high risk of rebleeding and treatment failure could preferably avoid early rebleeding and treatment failure based on reduction in HVPG ([@B4]) and have a higher rate of successful treatment ([@B7]; [@B3]) in the TIPS procedure. In the subgroup analysis, RCTs were associated with significantly higher improvement in 6-weeks survival and treatment failure in early-TIPS, which provided convincing evidence to support this outcome more effectively. Among these outcomes, a sensitivity analysis did not show a difference compared to previous results, which supported the reliability of this study more effectively.

As the most concerning complications, hepatic encephalopathy was not increased in the early-TIPS group, compared to standard therapy, which is consistent with previous a meta-analysis ([@B9]) and the AASLD guideline ([@B15] that considers no difference between the two interventions. Nevertheless, early-TIPS improved the risk of encephalopathy in non-RCTs. From five included studies, only one study by [@B23]) showed an increased effect on encephalopathy, while the others showed no difference between the two interventions. Additionally, the highest OR occurred in [@B22], in which patients with Child-Pugh A were enrolled, which might be a predictive factor for overt hepatic encephalopathy ([@B16]). Therefore, the performance of early-TIPS remains controversial. The other possible predictors, such as a higher patient age ([@B33]), being female ([@B16]), a high Child-Pugh score ([@B34]), indication for TIPS, hepatic arterial blood flow changes after TIPS, or type of stent, have been discussed in other studies ([@B28]; [@B2]; [@B1]). In addition, we also performed a sensitivity analysis without including Child-Pugh A patients, which demonstrated that early-TIPS would not increase the risk of hepatic encephalopathy. Child-Pugh A patients were normally in a compensated stage, which means that the liver function was acceptable for their body. The Child-Pugh A patients were barely suffering hepatic encephalopathy before the placement of early-TIPS, however, the placement of early-TIPS directed blood ammonia which could have moved through the liver without metabolizing, therefore we preferred to object to performing TIPS in patients with a Child-Pugh A classification. The potential publication bias was detected in this outcome, which might suggest the presence of language bias, or a lack of publication of small trials with opposing results. In addition, both RCTs and non-RCTs in the subgroup analysis showed no difference between the interventions, however, considering the pooled negative effect of including all studies, we assumed that this uncertainty might due to the scarcity of studies, therefore, newer and richer knowledge is required to prevent this considerable complication in further research. Another main complication which affected long-term survival was ascites ([@B15]), which showed a significantly lower risk in early-TIPS in our study, and which profited from the reduction in HVPG.

Long-term effects on early-TIPS demonstrated that 1-year survival in our study was certainly improved compared to standard therapy. Among these five included studies, RCTs ([@B12]; [@B22]) identified a significant improvement in 1-year survival in patients who received early-TIPS, which came down to the same conclusion in a previous meta-analysis ([@B9]). In addition, we assessed the relative risk of bleeding-related death, which demonstrated a significant reduction in bleeding-related death in the early-TIPS group, and also supports the previously mentioned conclusion that TIPS played a key role in decreasing HVPG ([@B4]). Therefore, this protective effect on improving long-term survival might be due to the reduction of bleeding-related death compared to standard therapy. The early-TIPS was also associated with lower 1-year rebleeding risk, which is consistent with previous studies ([@B9]). Nevertheless, RCTs showed no difference between the two interventions, which might suggest that the lack of studies affect the accuracy of the results. This issue could be solved in future by increased studies on this subject.

No difference between the two interventions was observed in patients who successfully underwent liver transplantation and might account for the fact that early-TIPS would not increase the risk of death due to liver failure. However, more patients in early-TIPS underwent liver transplantation. [@B9] considered that this outcome might be due to the reduction in treatment failure and rebleeding, which allows some patients with severe cirrhosis, who should not have met the criteria for transplantation, to use standard therapy and who could be enrolled in a transplantation list. In consideration of the improvement in treatment failure and short-term survival, without increasing liver failure death in early-TIPS patients, we assumed that the performance of early-TIPS could be an alternative treatment choice, to rescue more AVB patients by undergoing further liver transplantation. However, without addressing the global shortage of organ donations, this advantage is bound to be limited.

The most essential purpose for studies on treatment of AVB are to refine the target population that might benefit from early-TIPS ([@B15]). In other studies, patients with Child-Pugh B and C were equally associated with higher survival in the early-TIPS group, which was consistent with the previous study ([@B9]) and AASLD guideline ([@B15]). Although previous research considered that the reason there was no difference in terms of mortality in Child-Pugh B and Child-Pugh C patients, might be due a limited sample size, however, the result remained unchanged in this study, which suggests that patients with decompensated cirrhosis and AVB could consider receiving early-TIPS either in Child-Pugh B or Child-Pugh C, which is strongly supported in the current recommendation of the European Association for the Study of the Liver (EASL) clinical practice guidelines ([@B10]) of 2018. Nevertheless, in an observational study ([@B17]), patients with Child-Pugh B with AVB demonstrated a low mortality, and early-TIPS did not improve the survival compared to standard care (survival at 6 weeks: 94% vs. 90%; survival at 1 year: 77% vs. 75%). However, the rescue-TIPS was performed in their standard group, which might potentially improve the final outcomes of survival. Therefore, there is still no clear evidence that use of early-TIPS for AVB patients with Child-Pugh B is a predicting factor for bad prognosis. At present, early-TIPS is only recommended in high risk patients (Child-Pugh C and Child-Pugh B with acute variceal bleeding). Nevertheless, [@B23] considered that high risk patients only made up a small percentage of AVB, therefore, patients with Child-Pugh A and Child-Pugh B without AVB, were investigated in their study and it was found that in Child-Pugh A patients, the mortality in the standard treatment group was already low and no difference was observed compared to early-TIPS; in Child-Pugh B patients, improvement in survival was only observed in patients with AVB, and there was no benefit in survival in Child-Pugh B patients without AVB. As mentioned previously, the patients with Child-Pugh A might suffer a higher risk of encephalopathy compared to standard therapy. In conclusion, whether non-high-risk patients could benefit from early-TIPS requires further investigative research.

The advantages of our study are as follows: compared to the previous studies, we reported serval new endpoints and drew some new conclusion with several updated studies: (1) mortality and rebleeding rate at 6-weeks, which was considered the primary endpoint for studies for treatment of AVB, showed a significant reduction in early-TIPS; (2) early-TIPS does not increase risk of liver transplantation, which might provide evidence that AVB patients, who may die using standard therapy, could survive and eventually undergo liver transplantation; (3) early-TIPS showed a lower risk of bleeding-related death and new or worsening ascites, which could testify to the effect of reducing HVPG; (4) early-TIPS does not increase the risk of hepatic encephalopathy. We also assessed the long-term survival and subgroup analysis by Child-Pugh C and Child-Pugh B classification, which offered better evidence for clinicians to select patients who are appropriate for early-TIPS. Finally, a subgroup analysis with RCTs was performed to provide better evidence for uncertainties (long-term survival, hepatic encephalopathy and target population) on the latest clinical guidelines.

Limitation {#s4_1}
----------

Among the five included studies, four were published by two authors (Lv and Garcia-Pagan), which indicated that a large population came from only these two studies which might create a potential bias. Additionally, the scarcity of included studies and the deficiency in valuable outcomes should be considered as a limitation in this study, which might affect the accuracy of the results.

Conclusions {#s5}
===========

This meta-analysis revealed that in patients with AVB in cirrhosis, early covered-TIPS could rescue more patients, demonstrating a significant improvement in treatment failure, both in short- and long-term mortality, rebleeding risk, and new or worsening ascites compared to current standard therapy. The early-covered-TIPS could be recommended in the management of high-risk AVB patients with cirrhosis, except for patients with Child-Pugh A. In consideration of the scarcity of current evidence, further researches exploring solutions to prevent hepatic encephalopathy and refining selection criteria for early-covered-TIPS are required.
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